WO2007002447A3 - Compositions servant a traiter l'acne rosacee - Google Patents

Compositions servant a traiter l'acne rosacee Download PDF

Info

Publication number
WO2007002447A3
WO2007002447A3 PCT/US2006/024551 US2006024551W WO2007002447A3 WO 2007002447 A3 WO2007002447 A3 WO 2007002447A3 US 2006024551 W US2006024551 W US 2006024551W WO 2007002447 A3 WO2007002447 A3 WO 2007002447A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treating rosacea
disclosed
rosacea
pharmaceutical
Prior art date
Application number
PCT/US2006/024551
Other languages
English (en)
Other versions
WO2007002447A2 (fr
Inventor
Steven L Basta
Adam D Gridley
Original Assignee
Bioform Medical Inc
Steven L Basta
Adam D Gridley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioform Medical Inc, Steven L Basta, Adam D Gridley filed Critical Bioform Medical Inc
Publication of WO2007002447A2 publication Critical patent/WO2007002447A2/fr
Publication of WO2007002447A3 publication Critical patent/WO2007002447A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques et cosmétiques contenant en tant qu'ingrédients actifs une association d'au moins un composé aldéhyde aromatique porteur de groupe oxy, et d'un agent supplémentaire à action cosmétique ou pharmaceutique qui est efficace contre l'acnée rosacée. La présente invention se rapporte en outre aux utilisations de ces compositions.
PCT/US2006/024551 2005-06-23 2006-06-23 Compositions servant a traiter l'acne rosacee WO2007002447A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69353605P 2005-06-23 2005-06-23
US60/693,536 2005-06-23

Publications (2)

Publication Number Publication Date
WO2007002447A2 WO2007002447A2 (fr) 2007-01-04
WO2007002447A3 true WO2007002447A3 (fr) 2007-02-22

Family

ID=37441235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/024551 WO2007002447A2 (fr) 2005-06-23 2006-06-23 Compositions servant a traiter l'acne rosacee

Country Status (1)

Country Link
WO (1) WO2007002447A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2249765B1 (fr) * 2008-02-27 2019-11-13 Allergan, Inc. Dapsone pour traiter la rosacée
EP2313783A2 (fr) * 2008-07-18 2011-04-27 Galderma Research & Development Modulateurs de voie de signalisation pacap pour traiter des maladies inflammatoires de la peau avec une composante neurogène et plus particulièrement l acné rosacée et composition contenant ceux-ci
US20110305747A1 (en) * 2009-07-30 2011-12-15 Allergan, Inc. Combination of dapsone with other anti-acne agents

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006537A1 (fr) * 1988-01-15 1989-07-27 Curatek Pharmaceuticals, Inc. Formulations topiques de metronidazole et leurs emplois therapeutiques
WO2003043621A1 (fr) * 2001-11-16 2003-05-30 Cutanix Corporation Compositions pharmaceutiques et cosmetiques contenant des aldehydes aromatiques porteurs de groupes oxy
WO2004103233A1 (fr) * 2003-05-15 2004-12-02 Cutanix Corporation Compositions contenant un melange d'un agent pharmaceutique ou d'un agent cosmetique et d'un aldehyde aromatique de support de groupe oxy
US20040242588A1 (en) * 2003-05-27 2004-12-02 Jack Dejovin Compounds, formulations, and methods for treating or preventing rosacea

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006537A1 (fr) * 1988-01-15 1989-07-27 Curatek Pharmaceuticals, Inc. Formulations topiques de metronidazole et leurs emplois therapeutiques
WO2003043621A1 (fr) * 2001-11-16 2003-05-30 Cutanix Corporation Compositions pharmaceutiques et cosmetiques contenant des aldehydes aromatiques porteurs de groupes oxy
WO2004103233A1 (fr) * 2003-05-15 2004-12-02 Cutanix Corporation Compositions contenant un melange d'un agent pharmaceutique ou d'un agent cosmetique et d'un aldehyde aromatique de support de groupe oxy
US20040242588A1 (en) * 2003-05-27 2004-12-02 Jack Dejovin Compounds, formulations, and methods for treating or preventing rosacea

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SKINCARERX: "Cutanix Dramtic Relief for Sensitive Skin and Rosacea", 3 April 2005 (2005-04-03), pages 1 - 2, XP002409824, Retrieved from the Internet <URL:http://web.archive.org/web/20050403042254/http://skincarerx.com/cutanix.html> [retrieved on 20061130] *

Also Published As

Publication number Publication date
WO2007002447A2 (fr) 2007-01-04

Similar Documents

Publication Publication Date Title
WO2006096439A3 (fr) Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
WO2007127333A3 (fr) Compositions pour le traitement et la prévention du gonflement des paupières
WO2007127158A3 (fr) Modification d&#39;absorption percutanée de matériaux topiquement actifs
WO2004089357A3 (fr) Preparation antifongique a base de triterpene et d&#39;huile essentielle
WO2009061431A3 (fr) Compositions pour le traitement et la prévention du gonflement des paupières
WO2005079143A3 (fr) Formulations topiques pour le traitement d&#39;etats dermatologiques
WO2006056711A3 (fr) Medicament oral a liberation modifiee d&#39;au moins un principe actif sous forme multimicrocapsulaire
WO2006102610A3 (fr) Composes bicycloheteroaryle utilises en tant que modulateurs de p2x7 et leurs utilisations
WO2007002597A3 (fr) Formulations a liberation modifiee d&#39;un sel de bupropion
WO2006089114A3 (fr) Procedes et compositions pour le traitement d&#39;un sujet souffrant d&#39;un etat a mediation assuree par la toxine de l&#39;anthrax
WO2005117895A3 (fr) Compositions contenant de la meloxicame
WO2006121964A3 (fr) Compositions sous forme de suspensions de nepafenac et d&#39;autres medicaments ophtalmiques pour le traitement topique de troubles ophtalmiques
WO2007133751A3 (fr) Formulations de polyorthoester à base stabilisée
IL197212A0 (en) Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
WO2008042480A3 (fr) Inhibiteurs époxyde de cystéine protéases
BR0209327A (pt) Composição para tratamento de constipação induzida por drogas
WO2008070010A3 (fr) Rétablissement après une attaque
WO2006113718A3 (fr) Compositions destinees au traitement des neoplasmes
WO2008025830A3 (fr) Compositions d&#39;écran solaire
WO2007009691A3 (fr) Combinaison de substances active s
WO2002036129A3 (fr) Traitement topique de la mastalgie
WO2003035080A3 (fr) Procede de preparation de compositions pharmaceutiques servant a administrer localement des inhibiteurs de l&#39;enzyme cyclooxygenase-2
WO2004073615A8 (fr) Composes de deazaflavine et leurs methodes d&#39;utilisation
WO2007002447A3 (fr) Compositions servant a traiter l&#39;acne rosacee
WO2004071402A3 (fr) Forme pharmaceutique stable comprenant un inhibiteur de reductase hmg-coa

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06773873

Country of ref document: EP

Kind code of ref document: A2